APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Spasmolytic Injections

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Spasmolytic Injections Market Outlook and Growth Opportunities 2026

Report ID 174037140430 December 2025201 pages

Choose your research edition.

Industry ResearchSpasmolytic Injections Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Spasmolytic Injections Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Spasmolytic Injections Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Spasmolytic Injections Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Spasmolytic Injections Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Spasmolytic Injections market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Spasmolytic Injections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Spasmolytic Injections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Spasmolytic Injections is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Spasmolytic Injections market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Spasmolytic Injections market include AdvaCare Pharma, Allergan, Baxter International, Boehringer Ingelheim, Chengdu Better Pharmaceutical, CNS Therapeutics, Huarun Shuanghe, Ipsen and Medytox, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Spasmolytic Injections market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Spasmolytic Injections and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Spasmolytic Injections revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Spasmolytic Injections market.

Spasmolytic Injections Segment by Company

AdvaCare Pharma

Allergan

Baxter International

Boehringer Ingelheim

Chengdu Better Pharmaceutical

CNS Therapeutics

Huarun Shuanghe

Ipsen

Medytox

Nanjing Hangsheng Pharmaceutical

Sun Pharmaceutical Industries

Wanbangde Pharmaceutical Group

Wuhan Renfu Pharmaceutical

Zydus Cadila

Lilly

Mylan

Sanofi

Teva Pharmaceuticals

Spasmolytic Injections Segment by Type

Papaverines

Anticholinergics

Calcium Channel Blockers

Others

Spasmolytic Injections Segment by Application

Hospital

Clinic

Spasmolytic Injections Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Spasmolytic Injections status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Spasmolytic Injections key companies, revenue, market share, and recent developments.

3. To split the Spasmolytic Injections breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Spasmolytic Injections market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Spasmolytic Injections significant trends, drivers, influence factors in global and regions.

6. To analyze Spasmolytic Injections competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spasmolytic Injections market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Spasmolytic Injections and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spasmolytic Injections.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Spasmolytic Injections industry.

Chapter 3: Detailed analysis of Spasmolytic Injections company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Spasmolytic Injections in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Spasmolytic Injections in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Spasmolytic Injections Industry Trends Table 2. Spasmolytic Injections Industry Drivers Table 3. Spasmolytic Injections Industry Opportunities and Challenges Table 4. Spasmolytic Injections Industry Restraints Table 5. Global Spasmolytic Injections Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Spasmolytic Injections Revenue Share by Company (2021-2026) Table 7. Global Spasmolytic Injections Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Spasmolytic Injections Key Company Manufacturing Base & Headquarters Table 9. Global Spasmolytic Injections Company, Product Type & Application Table 10. Global Spasmolytic Injections Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Spasmolytic Injections by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Papaverines Table 15. Significant Companies of Anticholinergics Table 16. Significant Companies of Calcium Channel Blockers Table 17. Significant Companies of Others Table 18. Global Spasmolytic Injections Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Spasmolytic Injections Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Spasmolytic Injections Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Spasmolytic Injections Sales Value Share by Type (2021-2026) Table 22. Global Spasmolytic Injections Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Clinic Table 25. Global Spasmolytic Injections Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Spasmolytic Injections Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Spasmolytic Injections Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Spasmolytic Injections Sales Value Share by Application (2021-2026) Table 29. Global Spasmolytic Injections Sales Value Share by Application (2027-2032) Table 30. Global Spasmolytic Injections Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Spasmolytic Injections Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Spasmolytic Injections Sales Value Share by Region (2021-2026) Table 33. Global Spasmolytic Injections Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Spasmolytic Injections Sales Value Share by Region (2027-2032) Table 35. Global Spasmolytic Injections Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Spasmolytic Injections Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Spasmolytic Injections Sales Value Market Share by Country (2021-2026) Table 38. Global Spasmolytic Injections Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Spasmolytic Injections Sales Value Market Share by Country (2027-2032) Table 40. AdvaCare Pharma Company Information Table 41. AdvaCare Pharma Business Overview Table 42. AdvaCare Pharma Spasmolytic Injections Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. AdvaCare Pharma Spasmolytic Injections Product Portfolio Table 44. AdvaCare Pharma Recent Development Table 45. Allergan Company Information Table 46. Allergan Business Overview Table 47. Allergan Spasmolytic Injections Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Allergan Spasmolytic Injections Product Portfolio Table 49. Allergan Recent Development Table 50. Baxter International Company Information Table 51. Baxter International Business Overview Table 52. Baxter International Spasmolytic Injections Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Baxter International Spasmolytic Injections Product Portfolio Table 54. Baxter International Recent Development Table 55. Boehringer Ingelheim Company Information Table 56. Boehringer Ingelheim Business Overview Table 57. Boehringer Ingelheim Spasmolytic Injections Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Boehringer Ingelheim Spasmolytic Injections Product Portfolio Table 59. Boehringer Ingelheim Recent Development Table 60. Chengdu Better Pharmaceutical Company Information Table 61. Chengdu Better Pharmaceutical Business Overview Table 62. Chengdu Better Pharmaceutical Spasmolytic Injections Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Chengdu Better Pharmaceutical Spasmolytic Injections Product Portfolio Table 64. Chengdu Better Pharmaceutical Recent Development Table 65. CNS Therapeutics Company Information Table 66. CNS Therapeutics Business Overview Table 67. CNS Therapeutics Spasmolytic Injections Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. CNS Therapeutics Spasmolytic Injections Product Portfolio Table 69. CNS Therapeutics Recent Development Table 70. Huarun Shuanghe Company Information Table 71. Huarun Shuanghe Business Overview Table 72. Huarun Shuanghe Spasmolytic Injections Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Huarun Shuanghe Spasmolytic Injections Product Portfolio Table 74. Huarun Shuanghe Recent Development Table 75. Ipsen Company Information Table 76. Ipsen Business Overview Table 77. Ipsen Spasmolytic Injections Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Ipsen Spasmolytic Injections Product Portfolio Table 79. Ipsen Recent Development Table 80. Medytox Company Information Table 81. Medytox Business Overview Table 82. Medytox Spasmolytic Injections Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Medytox Spasmolytic Injections Product Portfolio Table 84. Medytox Recent Development Table 85. Nanjing Hangsheng Pharmaceutical Company Information Table 86. Nanjing Hangsheng Pharmaceutical Business Overview Table 87. Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Product Portfolio Table 89. Nanjing Hangsheng Pharmaceutical Recent Development Table 90. Sun Pharmaceutical Industries Company Information Table 91. Sun Pharmaceutical Industries Business Overview Table 92. Sun Pharmaceutical Industries Spasmolytic Injections Sales (L), Value (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 93. Sun Pharmaceutical Industries Spasmolytic Injections Product Portfolio Table 94. Sun Pharmaceutical Industries Recent Development Table 95. Wanbangde Pharmaceutical Group Company Information Table 96. Wanbangde Pharmaceutical Group Business Overview Table 97. Wanbangde Pharmaceutical Group Spasmolytic Injections Sales (L), Value (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 98. Wanbangde Pharmaceutical Group Spasmolytic Injections Product Portfolio Table 99. Wanbangde Pharmaceutical Group Recent Development Table 100. Wuhan Renfu Pharmaceutical Company Information Table 101. Wuhan Renfu Pharmaceutical Business Overview Table 102. Wuhan Renfu Pharmaceutical Spasmolytic Injections Sales (L), Value (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 103. Wuhan Renfu Pharmaceutical Spasmolytic Injections Product Portfolio Table 104. Wuhan Renfu Pharmaceutical Recent Development Table 105. Zydus Cadila Company Information Table 106. Zydus Cadila Business Overview Table 107. Zydus Cadila Spasmolytic Injections Sales (L), Value (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 108. Zydus Cadila Spasmolytic Injections Product Portfolio Table 109. Zydus Cadila Recent Development Table 110. Lilly Company Information Table 111. Lilly Business Overview Table 112. Lilly Spasmolytic Injections Sales (L), Value (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 113. Lilly Spasmolytic Injections Product Portfolio Table 114. Lilly Recent Development Table 115. Mylan Company Information Table 116. Mylan Business Overview Table 117. Mylan Spasmolytic Injections Sales (L), Value (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 118. Mylan Spasmolytic Injections Product Portfolio Table 119. Mylan Recent Development Table 120. Sanofi Company Information Table 121. Sanofi Business Overview Table 122. Sanofi Spasmolytic Injections Sales (L), Value (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 123. Sanofi Spasmolytic Injections Product Portfolio Table 124. Sanofi Recent Development Table 125. Teva Pharmaceuticals Company Information Table 126. Teva Pharmaceuticals Business Overview Table 127. Teva Pharmaceuticals Spasmolytic Injections Sales (L), Value (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 128. Teva Pharmaceuticals Spasmolytic Injections Product Portfolio Table 129. Teva Pharmaceuticals Recent Development Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Spasmolytic Injections Product Image Figure 2. Global Spasmolytic Injections Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Spasmolytic Injections Market Size (2021-2032) & (US$ Million) Figure 4. Global Spasmolytic Injections Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Papaverines Image Figure 8. Anticholinergics Image Figure 9. Calcium Channel Blockers Image Figure 10. Others Image Figure 11. Global Spasmolytic Injections Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Spasmolytic Injections Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Spasmolytic Injections Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Clinic Image Figure 16. Global Spasmolytic Injections Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Spasmolytic Injections Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Spasmolytic Injections Sales Value Share by Application (2021-2032) Figure 19. Global Spasmolytic Injections Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Spasmolytic Injections Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Spasmolytic Injections Sales Value (2021-2032) & (US$ Million) Figure 22. North America Spasmolytic Injections Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Spasmolytic Injections Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Spasmolytic Injections Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Spasmolytic Injections Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Spasmolytic Injections Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Spasmolytic Injections Sales Value (2021-2032) & (US$ Million) Figure 28. South America Spasmolytic Injections Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Spasmolytic Injections Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Spasmolytic Injections Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Spasmolytic Injections Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Papaverines
  • Anticholinergics
  • Calcium Channel Blockers
  • Others
Applications
  • Hospital
  • Clinic
Companies covered
  • AdvaCare Pharma
  • Allergan
  • Baxter International
  • Boehringer Ingelheim
  • Chengdu Better Pharmaceutical
  • CNS Therapeutics
  • Huarun Shuanghe
  • Ipsen
  • Medytox
  • Nanjing Hangsheng Pharmaceutical
  • Sun Pharmaceutical Industries
  • Wanbangde Pharmaceutical Group
  • Wuhan Renfu Pharmaceutical
  • Zydus Cadila
  • Lilly
  • Mylan
  • Sanofi
  • Teva Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Spasmolytic Injections Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Spasmolytic Injections Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Spasmolytic Injections Market Dynamics
  1. 2.1 Spasmolytic Injections Industry Trends
  2. 2.2 Spasmolytic Injections Industry Drivers
  3. 2.3 Spasmolytic Injections Industry Opportunities and Challenges
  4. 2.4 Spasmolytic Injections Industry Restraints
3 Spasmolytic Injections Market by Company
  1. 3.1 Global Spasmolytic Injections Company Revenue Ranking in 2025
  2. 3.2 Global Spasmolytic Injections Revenue by Company (2021-2026)
  3. 3.3 Global Spasmolytic Injections Company Ranking (2024-2026)
  4. 3.4 Global Spasmolytic Injections Company Manufacturing Base and Headquarters
  5. 3.5 Global Spasmolytic Injections Company Product Type and Application
  6. 3.6 Global Spasmolytic Injections Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Spasmolytic Injections Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Spasmolytic Injections Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Spasmolytic Injections Market by Type
  1. 4.1 Spasmolytic Injections Type Introduction
  2. 4.1.1 Papaverines
  3. 4.1.2 Anticholinergics
  4. 4.1.3 Calcium Channel Blockers
  5. 4.1.4 Others
  6. 4.2 Global Spasmolytic Injections Sales Value by Type
  7. 4.2.1 Global Spasmolytic Injections Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Spasmolytic Injections Sales Value by Type (2021-2032)
  9. 4.2.3 Global Spasmolytic Injections Sales Value Share by Type (2021-2032)
5 Spasmolytic Injections Market by Application
  1. 5.1 Spasmolytic Injections Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Spasmolytic Injections Sales Value by Application
  5. 5.2.1 Global Spasmolytic Injections Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Spasmolytic Injections Sales Value by Application (2021-2032)
  7. 5.2.3 Global Spasmolytic Injections Sales Value Share by Application (2021-2032)
6 Spasmolytic Injections Regional Value Analysis
  1. 6.1 Global Spasmolytic Injections Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Spasmolytic Injections Sales Value by Region (2021-2032)
  3. 6.2.1 Global Spasmolytic Injections Sales Value by Region: 2021-2026
  4. 6.2.2 Global Spasmolytic Injections Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Spasmolytic Injections Sales Value (2021-2032)
  7. 6.3.2 North America Spasmolytic Injections Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Spasmolytic Injections Sales Value (2021-2032)
  10. 6.4.2 Europe Spasmolytic Injections Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Spasmolytic Injections Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Spasmolytic Injections Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Spasmolytic Injections Sales Value (2021-2032)
  16. 6.6.2 South America Spasmolytic Injections Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Spasmolytic Injections Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Spasmolytic Injections Sales Value Share by Country, 2025 VS 2032
7 Spasmolytic Injections Country-level Value Analysis
  1. 7.1 Global Spasmolytic Injections Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Spasmolytic Injections Sales Value by Country (2021-2032)
  3. 7.2.1 Global Spasmolytic Injections Sales Value by Country (2021-2026)
  4. 7.2.2 Global Spasmolytic Injections Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Spasmolytic Injections Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Spasmolytic Injections Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Spasmolytic Injections Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AdvaCare Pharma
  2. 8.1.1 AdvaCare Pharma Company Information
  3. 8.1.2 AdvaCare Pharma Business Overview
  4. 8.1.3 AdvaCare Pharma Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AdvaCare Pharma Spasmolytic Injections Product Portfolio
  6. 8.1.5 AdvaCare Pharma Recent Developments
  7. 8.2 Allergan
  8. 8.2.1 Allergan Company Information
  9. 8.2.2 Allergan Business Overview
  10. 8.2.3 Allergan Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Allergan Spasmolytic Injections Product Portfolio
  12. 8.2.5 Allergan Recent Developments
  13. 8.3 Baxter International
  14. 8.3.1 Baxter International Company Information
  15. 8.3.2 Baxter International Business Overview
  16. 8.3.3 Baxter International Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Baxter International Spasmolytic Injections Product Portfolio
  18. 8.3.5 Baxter International Recent Developments
  19. 8.4 Boehringer Ingelheim
  20. 8.4.1 Boehringer Ingelheim Company Information
  21. 8.4.2 Boehringer Ingelheim Business Overview
  22. 8.4.3 Boehringer Ingelheim Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Boehringer Ingelheim Spasmolytic Injections Product Portfolio
  24. 8.4.5 Boehringer Ingelheim Recent Developments
  25. 8.5 Chengdu Better Pharmaceutical
  26. 8.5.1 Chengdu Better Pharmaceutical Company Information
  27. 8.5.2 Chengdu Better Pharmaceutical Business Overview
  28. 8.5.3 Chengdu Better Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Chengdu Better Pharmaceutical Spasmolytic Injections Product Portfolio
  30. 8.5.5 Chengdu Better Pharmaceutical Recent Developments
  31. 8.6 CNS Therapeutics
  32. 8.6.1 CNS Therapeutics Company Information
  33. 8.6.2 CNS Therapeutics Business Overview
  34. 8.6.3 CNS Therapeutics Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CNS Therapeutics Spasmolytic Injections Product Portfolio
  36. 8.6.5 CNS Therapeutics Recent Developments
  37. 8.7 Huarun Shuanghe
  38. 8.7.1 Huarun Shuanghe Company Information
  39. 8.7.2 Huarun Shuanghe Business Overview
  40. 8.7.3 Huarun Shuanghe Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Huarun Shuanghe Spasmolytic Injections Product Portfolio
  42. 8.7.5 Huarun Shuanghe Recent Developments
  43. 8.8 Ipsen
  44. 8.8.1 Ipsen Company Information
  45. 8.8.2 Ipsen Business Overview
  46. 8.8.3 Ipsen Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ipsen Spasmolytic Injections Product Portfolio
  48. 8.8.5 Ipsen Recent Developments
  49. 8.9 Medytox
  50. 8.9.1 Medytox Company Information
  51. 8.9.2 Medytox Business Overview
  52. 8.9.3 Medytox Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Medytox Spasmolytic Injections Product Portfolio
  54. 8.9.5 Medytox Recent Developments
  55. 8.10 Nanjing Hangsheng Pharmaceutical
  56. 8.10.1 Nanjing Hangsheng Pharmaceutical Company Information
  57. 8.10.2 Nanjing Hangsheng Pharmaceutical Business Overview
  58. 8.10.3 Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Product Portfolio
  60. 8.10.5 Nanjing Hangsheng Pharmaceutical Recent Developments
  61. 8.11 Sun Pharmaceutical Industries
  62. 8.11.1 Sun Pharmaceutical Industries Company Information
  63. 8.11.2 Sun Pharmaceutical Industries Business Overview
  64. 8.11.3 Sun Pharmaceutical Industries Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sun Pharmaceutical Industries Spasmolytic Injections Product Portfolio
  66. 8.11.5 Sun Pharmaceutical Industries Recent Developments
  67. 8.12 Wanbangde Pharmaceutical Group
  68. 8.12.1 Wanbangde Pharmaceutical Group Company Information
  69. 8.12.2 Wanbangde Pharmaceutical Group Business Overview
  70. 8.12.3 Wanbangde Pharmaceutical Group Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Wanbangde Pharmaceutical Group Spasmolytic Injections Product Portfolio
  72. 8.12.5 Wanbangde Pharmaceutical Group Recent Developments
  73. 8.13 Wuhan Renfu Pharmaceutical
  74. 8.13.1 Wuhan Renfu Pharmaceutical Company Information
  75. 8.13.2 Wuhan Renfu Pharmaceutical Business Overview
  76. 8.13.3 Wuhan Renfu Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Wuhan Renfu Pharmaceutical Spasmolytic Injections Product Portfolio
  78. 8.13.5 Wuhan Renfu Pharmaceutical Recent Developments
  79. 8.14 Zydus Cadila
  80. 8.14.1 Zydus Cadila Company Information
  81. 8.14.2 Zydus Cadila Business Overview
  82. 8.14.3 Zydus Cadila Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Zydus Cadila Spasmolytic Injections Product Portfolio
  84. 8.14.5 Zydus Cadila Recent Developments
  85. 8.15 Lilly
  86. 8.15.1 Lilly Company Information
  87. 8.15.2 Lilly Business Overview
  88. 8.15.3 Lilly Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Lilly Spasmolytic Injections Product Portfolio
  90. 8.15.5 Lilly Recent Developments
  91. 8.16 Mylan
  92. 8.16.1 Mylan Company Information
  93. 8.16.2 Mylan Business Overview
  94. 8.16.3 Mylan Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Mylan Spasmolytic Injections Product Portfolio
  96. 8.16.5 Mylan Recent Developments
  97. 8.17 Sanofi
  98. 8.17.1 Sanofi Company Information
  99. 8.17.2 Sanofi Business Overview
  100. 8.17.3 Sanofi Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Sanofi Spasmolytic Injections Product Portfolio
  102. 8.17.5 Sanofi Recent Developments
  103. 8.18 Teva Pharmaceuticals
  104. 8.18.1 Teva Pharmaceuticals Company Information
  105. 8.18.2 Teva Pharmaceuticals Business Overview
  106. 8.18.3 Teva Pharmaceuticals Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Teva Pharmaceuticals Spasmolytic Injections Product Portfolio
  108. 8.18.5 Teva Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst